Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Systems, Ace Biosciences and Genmab, Amersham Biosciences

Premium

Proteome Systems uses AP Clinical’s services

Proteome Systems of Sydney, Australia, has begun working with AP Clinical, a startup Sydney-based biomedical consulting company, to acquire clinical samples from hospitals around the world for its proteomics discovery research, ProteoMonitor learned last week. AP Clinical will serve as Proteome Systems’ liason to hospitals in Australia, South Africa, and China, among other countries, said Marc Wilkins, Proteome Systems’ executive vice president for discovery and bioinformatics. Keith Williams, Proteome Systems’ CEO, also serves as a director of AP Clinical.

 

Ace Biosciences teams with Genmab

Ace Biosciences and Genmab have agreed to jointly investigate the potential for creating antibody-based therapeutics to protein targets identified by Ace, the two companies said last week. Genmab and Ace BioSciences will collaborate on the research, development, and commercialization of the new antibody products, and will share equally in the development costs and revenues generated from out-licensing or sales of these products.

Odense, Denmark-based Ace and Genmab of Copenhagen, will jointly study at least four protein targets over the next three years, said Ejbind Mortz, CEO of Ace. “If everything works out fine I think there’ll be more,” he added. Ace is currently focusing its efforts on finding protein targets associated with infectious bacteria including Campylobacter jejuni and Klebsiella pneumoniae. The company’s proteomics platform consists of traditional 2D gel- and chromatography-based separation schemes, coupled with electrospray LC/MS and Micromass Q-TOF mass spectrometers, Mortz said. The company also employs both in vitro and in vivo affinity pull-down techniques for investigating protein-protein interactions, Mortz added.

 

Amersham to Acquire Cimarron Software

Amersham Biosciences said last week it will acquire a controlling stake in informatics company Cimarron Software, and has the option to acquire all of the Salt Lake City-based company over the next three years. Jerry Walker, vice president for informatics at Amersham, said that the companies, which have worked together since 1996, plan to launch Scierra later this year. The product lets researchers perform tracking and analysis in proteomics, gene-expression analysis, genotyping, and DNA sequencing. Cimarron employs 60 software designers, programmers, automation engineers, and other scientists, according to Amersham.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.